Keel Point LLC Purchases 148 Shares of Zoetis Inc. (NYSE:ZTS)

Keel Point LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 7.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,173 shares of the company’s stock after buying an additional 148 shares during the period. Keel Point LLC’s holdings in Zoetis were worth $429,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Wellington Management Group LLP boosted its stake in Zoetis by 2.5% during the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after purchasing an additional 297,044 shares during the last quarter. Morgan Stanley boosted its stake in Zoetis by 34.6% during the 4th quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after purchasing an additional 2,796,694 shares during the last quarter. Geode Capital Management LLC boosted its stake in Zoetis by 0.3% during the 1st quarter. Geode Capital Management LLC now owns 9,739,370 shares of the company’s stock valued at $1,617,464,000 after purchasing an additional 27,097 shares during the last quarter. Northern Trust Corp boosted its stake in Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock valued at $1,068,804,000 after purchasing an additional 196,771 shares during the last quarter. Finally, Norges Bank acquired a new position in Zoetis during the 4th quarter valued at about $745,861,000. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 0.3 %

NYSE:ZTS opened at $149.37 on Tuesday. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $68.32 billion, a PE ratio of 29.55, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The firm’s 50 day moving average is $179.11 and its 200 day moving average is $180.74. Zoetis Inc. has a 12 month low of $148.48 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the firm posted $1.15 EPS. Sell-side analysts expect that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.16%. Zoetis’s dividend payout ratio (DPR) is presently 33.93%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at approximately $4,037,257.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have sold 2,209 shares of company stock valued at $408,453. 0.12% of the stock is owned by company insiders.

Analysts Set New Price Targets

ZTS has been the subject of a number of analyst reports. Barclays lifted their price target on Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. Piper Sandler lifted their price target on Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a research note on Tuesday, February 20th. Jefferies Financial Group restated a “buy” rating and issued a $230.00 target price on shares of Zoetis in a research note on Tuesday, December 19th. Stifel Nicolaus cut their target price on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Finally, The Goldman Sachs Group boosted their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $224.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.